1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
149 recruiting
1
Rare Diseases
across 2 areas
0
News (30d)
Quiet
ABLi Therapeutics, Inc. is a company with 1 orphan drug designation across 1 rare disease.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| multiple system atrophy | N-(4-Methyl-3-(4-(5-(4-methylisoxazol-5-yl)pyridine-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide succinate | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio